心玮医疗-B(06609)发布公告，该公司于2025年9月25日斥资370.59万港元回购5.98万股股份，每股回购 价格为60.9-63.15港元。 ...

智通财经APP讯，心玮医疗-B(06609)发布公告，该公司于2025年9月25日斥资370.59万港元回购5.98万股 股份，每股回购价格为60.9-63.15港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期： 2025年9月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 ...

Core Viewpoint - The company has achieved over 40% revenue growth and over 50% gross profit growth in the first half of the year, successfully turning a profit and marking a significant step towards scalable profitability [1][2]. Financial Performance - The company's revenue reached 186 million yuan, a year-on-year increase of 44.4%, demonstrating strong internal growth and risk resilience [2]. - Gross profit amounted to 127 million yuan, a substantial increase of 53.9%, with a gross margin of 68.2%, up 4.2 percentage points from the previous year [2]. - The net profit attributable to shareholders was 50.9 million yuan, indicating a successful turnaround from previous losses [2]. Product Development and Market Expansion - The company launched several new products, including the first domestic aneurysm embolization assist stent, which has significantly boosted revenue from hemorrhagic business by 563% [3]. - The ischemic product matrix has been continuously iterated, with the number of hospitals using large-bore aspiration catheters increasing by 267%, leading to a 60% increase in overall ischemic product implantation [3]. - The company has 32 products approved by NMPA, three by FDA, and one with CE marking, covering a wide range of treatments for ischemic and hemorrhagic strokes [4]. Valuation and Market Confidence - The company is currently in a valuation repair phase, with a PS ratio of 6.51, significantly below its historical average of 15.18, indicating substantial room for valuation improvement [5]. - To enhance market confidence, the company has initiated a stock buyback plan, committing 800 million HKD, reflecting a strong commitment to shareholder returns [1][5].

Group 1 - The company, Heartway Medical-B (06609), announced a share buyback on September 24, 2025, spending HKD 1.81 million to repurchase 30,000 shares [1] - The buyback price per share ranged from HKD 57.4 to HKD 62.45 [1]

Group 1 - The company, Heartway Medical-B (06609), announced a share buyback plan on September 24, 2025, involving an expenditure of HKD 1.81 million to repurchase 30,000 shares [1] - The repurchase price per share ranges from HKD 57.4 to HKD 62.45 [1]

格隆汇9月25日丨心玮医疗-B(06609.HK)发布公告，2025年9月24日耗资181万港元回购3万股，回购价格 每股57.4-62.45港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期： 2025年9月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 ...

中期報告 INTERIM REPORT 2025 INTERI M REPO R T 2025 中期報告 目錄 執行董事 王國輝先生 （董事長、首席執行官） 張坤女士 韋家威先生 （副總經理） 非執行董事 丁魁先生 陳少雄先生 陳剛先生 獨立非執行董事 郭少牧先生 馮向前先生 龔平先生 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 4 | | 管理層討論與分析 | 5 | | 企業管治及其他資料 | 23 | | 獨立審閱報告 | 32 | | 中期簡明綜合損益及其他全面收益表 | 33 | | 中期簡明綜合財務狀況表 | 34 | | 中期簡明綜合權益變動表 | 36 | | 中期簡明綜合現金流量表 | 37 | | 中期簡明綜合財務資料附註 | 39 | | 釋義 | 50 | 2 上海心瑋醫療科技股份有限公司 公司資料 董事會 審計委員會 龔平先生 （主席） 馮向前先生 丁魁先生 薪酬委員會 郭少牧先生 （主席） 龔平先生 王國輝先生 提名委員會 馮向前先生 （主席） 郭少牧先生 張坤女士 （於2025年3月27日任職） 王國輝先生 （於2025年3月27日不再為成員） 戰略委 ...

Key Points Summary Market Performance - The Hang Seng Index closed at 26,544, down 1.35% for the day but up 32.33% year-to-date [1] - The Hang Seng Tech Index closed at 6,271, down 0.99% for the day and up 40.36% year-to-date [1] - The CSI 300 Index closed at 4,498, down 1.16% for the day and up 14.31% year-to-date [1] - The Dow Jones Index closed at 46,142, up 0.27% for the day and up 8.46% year-to-date [1] Currency and Commodity Trends - The Renminbi Index is at 96.600, up 0.58% over the last month but down 2.47% over the last six months [2] - Brent crude oil is priced at $67.76 per barrel, up 2.85% over the last month but down 0.51% over the last six months [2] - Gold is priced at $3,668.34 per ounce, up 10.05% over the last month and up 20.86% over the last six months [2] Company News - Alibaba's AliExpress has received conditional approval to form a joint venture with South Korea's Shinsegae [5][14] - Huawei plans to launch its self-developed Ascend 950PR chip in the first quarter of next year [5][16] - The China Securities Regulatory Commission reported that the shareholding of Shankai Holdings is highly concentrated, with 24% held by 20 shareholders [5][17][18] Economic Indicators - Initial jobless claims in the U.S. fell to 231,000, below expectations, indicating a strengthening labor market [5][11] - The Bank of England's interest rate remains at 4.00%, unchanged from the previous period [5][12][13] - Reports indicate that China has terminated its antitrust investigation into Android ahead of U.S.-China talks [5][15] Stock Market Movements - The Hong Kong stock market experienced significant volatility, with the Hang Seng Index reaching a four-year high before closing lower [5][6] - Semiconductor-related stocks saw gains, with Hua Hong Semiconductor rising nearly 9% [5][6] - The A-share market showed weakness, with major indices closing down over 1% [6] Upcoming Economic Data - Key economic data releases include the Eurozone consumer confidence index and U.S. manufacturing PMI [5][29]